2.90
-0.11 (-3.65%)
| Penutupan Terdahulu | 3.01 |
| Jumlah Dagangan | 4,416 |
| Harga / Jualan (P/S) | 3.56 |
| Harga / Buku (P/B) | 0.080 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -34,814.94% |
| EPS Cair (TTM) | 0.660 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -58.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.70% |
| Nisbah Semasa (MRQ) | 1.05 |
| Aliran Tunai Operasi (OCF TTM) | -7.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -6.06 M |
| Pulangan Atas Aset (ROA TTM) | -14.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.92% |
AISkor Stockmoo
| Nilai 30% | -1.4 |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -4.6 |
| Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.0 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Sentimen Pegangan info | NA |
| Sentimen Berita info | NA |
| Wang Pintar 20% | 2.7 |
| Institusi bersih +2.54% daripada saham dalam pemfailan 13F terkini: 8 pemegang menambah, 5 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -88.5% dari 31 Aug hingga 30 Oct 2026, 3.1 hari untuk tutup (FINRA). info | |
| Aktiviti Orang Dalam info | NA |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info | |
| Di bawah garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga di antara sokongan dan rintangan. Paras sokongan dan rintangan menaik. info | |
| Skor Akhir | -1.48 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Pharmaceutical Retailers (US) | Bercampur | Bercampur |
| Pharmaceutical Retailers (Global) | Bercampur | Bercampur | |
| Stok | Scienture Holdings, Inc. | Bercampur | - |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| SCNX | - | - | - | 0.080 | -1.5 |
| WBA | 10 B | 4.34% | - | 1.44 | -2.0 |
| PETS | 19 M | - | - | 1.18 | -3.9 |
| RDGT | 853 K | - | - | 0.020 | -2.2 |
| MEDS | - | - | - | - | -2.1 |
| HITI | 199 M | - | - | 2.95 | -1.7 |
|
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders. |
|
| Sektor | Healthcare |
| Industri | Pharmaceutical Retailers |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 32.59% |
| % Dimiliki oleh Institusi | 1.35% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 6.24%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 8 | 41,998 |
| Berkurang | 5 | 7,231 |
| Baharu | 2 | 15,999 |
| Dijual habis | 1 | 5 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 117,350 | 3.1 |
| 15 Oct 2026 | 105,863 | 1.0 |
| 30 Sep 2026 | 1,304,235 | 1.0 |
| 15 Sep 2026 | 1,249,889 | 1.2 |
| 31 Aug 2026 | 1,022,272 | 2.6 |
| 14 Aug 2026 | 1,607,698 | 1.0 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Oct 2026 | Yahoo Finance |
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™ Two FDA-Approved Commercial Products Position Company for Continued Sequential Revenue Growth High Gross Margins and… |
| 13 Oct 2026 | Yahoo Finance |
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
Continued Arbli™ sales growth, combined with REZENOPY™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth Arbli™ wholesale unit sales increased 74% sequentially, with recent institutional formulary additions supporting continued commercial… |
| 13 Oct 2026 | Yahoo Finance |
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
Scienture Holdings Inc. (NASDAQ:SCNX) on Tuesday reported preliminary third-quarter revenue of approximately $1.22 million, up 256% from $344,000 in the previous quarter. The pharmaceutical company’s revenue growth reflected rising sales of its blood pressure medication, Arbli, and initial… |
| 02 Oct 2026 | Yahoo Finance |
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Major Institutional Formulary Win Expands Arbli™’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli™ Addresses an Approximately $219 Million U.S. Losartan Market Representing Approximately 72 Million Prescriptions Annually COMMACK, NY, Oct. 02, 2026 (GLOBE… |
| 02 Oct 2026 | Yahoo Finance |
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Scienture Holdings Inc. (NASDAQ:SCNX) on Friday announced that three leading U.S. pediatric academic medical centers added its proprietary hypertension medication to their formularies. These specialized hospitals, which focus on treating children with severe and chronic medical conditions, now… |
| 30 Sep 2026 | Yahoo Finance |
Scienture Holdings, Inc. Announces Reverse Stock Split
COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization… |
| 22 Sep 2026 | Yahoo Finance |
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
Agreement provides dedicated commercial channel for REZENOPY™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States According to IQVIA data (MAT July 2026), the U.S. naloxone market generated approximately $140 million… |
| 09 Sep 2026 | Yahoo Finance |
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
Management to Highlight Growing Commercial Momentum of Arbli™ and the Commercial Launch of REZENOPY™ COMMACK, NY, Sept. 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on… |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 19 Jul 2024 | 08 Jul 2024 | 24 Jul 2024 | 1.5 Tunai |
| 25 Mar 2024 | 28 Feb 2024 | 22 Mar 2024 | 8 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2024 | 9.50 | 2 | 157.03 |
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |